Formation Bio
Jennifer Kang is an accomplished leader in program management and R&D portfolio management, currently serving as Director of Program Management at Formation Bio since March 2024. Previously, Jennifer held key positions at Vaxxinity, where as Director and Senior Director of Portfolio Management, innovative project planning and enhanced transparency were achieved through the development of a clinical study project plan template and cross-functional dashboards. Jennifer led a global Phase 3 trial for the COVID program, significantly contributing to the successful submission of a Marketing Approval Application. Additional experiences include serving as Chief of Staff in R&D at United Neuroscience, managing biosample operations at Roche, and leading bioanalytical strategy at Regeneron Pharmaceuticals. Jennifer holds a Bachelor of Science degree in Biological Sciences from the University of Notre Dame.
Formation Bio
5 followers
Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.